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Abstract
 
The Epstein-Barr virus (EBV)-encoded nuclear antigen 1 (EBNA1) is expressed in all EBV-
associated tumors, making it an important target for immunotherapy. However, evidence for
major histocompatibility complex (MHC) class I–restricted EBNA1 peptides endogenously
presented by EBV-transformed B and tumor cells remains elusive. Here we describe for the first
time the identification of an endogenously processed human histocompatibility leukocyte antigen
 
(HLA)-B8–restricted EBNA1 peptide that is recognized by CD8
 
  
 
T cells. T cell recognition
could be inhibited by the treatment of target cells with proteasome inhibitors that block the
MHC class I antigen processing pathway, but not by an inhibitor (chloroquine) of MHC class II
antigen processing. We also demonstrate that new protein synthesis is required for the generation
of the HLA-B8 epitope for T cell recognition, suggesting that defective ribosomal products
(DRiPs) are the major source of T cell epitopes. Experiments with protease inhibitors indicate
that some serine proteases may participate in the degradation of EBNA1 DRiPs before they are
further processed by proteasomes. These findings not only provide the first evidence of the
presentation of an MHC class I–restricted EBNA1 epitope to CD8
 
  
 
T cells, but also offer new
insight into the molecular mechanisms involved in the processing and presentation of EBNA1.
Key words: cancer vaccines • immunotherapy • MHC class I–restricted peptides • 
antigen presentation • CD8
 
  
 
T cells
 
Introduction
 
EBV, a human 
 
  
 
herpesvirus with tropism for B cells, has
been implicated in the pathogenesis of a variety of human
tumors, including Burkitt’s lymphoma (BL), posttransplant
lymphoproliferative disorder, nasopharyngeal carcinoma
(NPC), and Hodgkin’s disease (HD; 1, 2). Although a subset
of genes is responsible for the growth-transforming function
of EBV, EBV-encoded nuclear antigen 1 (EBNA1) is the
only viral gene that is detected in all EBV-associated tumors
(BL, NPC, posttransplant lymphoproliferative disorder, and
HD), and is critical for the maintenance of the viral episome
and the pathogenesis of EBV-associated tumors (3, 4). Al-
though two additional viral antigens, the latent membrane
proteins 1 and 2, are expressed in NPC and HD (type II
latency tumors) but not BL (type I latency tumor), expression
of the remaining viral genes is undetectable in type I or II
latency tumors. Thus, EBNA1 is a potentially important
target for immunotherapy of EBV-associated malignancies.
Although much effort has been directed toward the
identification of MHC class I–restricted endogenously pro-
cessed EBNA1 peptides, no such epitopes have been reported
(4, 5). For example, EBNA1-specific CD8
 
  
 
T cells could
be generated from human PBMCs after in vitro stimulation
with EBV-transformed B lymphoblastoid cell lines (LCLs)
pulsed with the exogenous EBNA1 protein, but they failed
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to recognize virally infected target cells such as LCLs or BL
tumor cells (5–7). The failure of T cells to recognize EBV-
infected cells has been largely attributed to the Gly-Ala re-
peat (GAr) domain within the EBNA1 protein, which
blocks endogenous antigen processing and presentation by
MHC class I molecules (6–8). However, several MHC class
II–restricted T cell epitopes have recently been identified
(9–11), suggesting that the processing and presentation of
EBNA1 through MHC class II pathway are not inhibited
by the GAr domain.
In this study we established EBNA1-reactive CD8
 
  
 
T
cell lines/clones from human PBMCs stimulated with
EBNA1 peptides. We show for the first time that these
peptide-induced CD8
 
  
 
T cells can recognize LCLs as well
as target cells transfected with the EBNA1 and HLA-B8
cDNAs based on cytokine release and cytotoxic assays. T
cell recognition of EBNA1 can be blocked by proteasome
inhibitors, but not by an inhibitor of MHC class II path-
way, suggesting that the EBNA1 peptide is generated
through the MHC class I pathway. We show further that
treatment of target cells with an irreversible protein synthe-
sis inhibitor, emetine, results in significant inhibition of the
presentation of the HLA-B8 T cell epitope for T cell rec-
ognition, suggesting that T cell epitopes are derived pri-
marily from the defective ribosomal products (DRiPs). We
also identified two protease inhibitors (AEBSF and TPCK)
that block antigen processing and presentation of the HLA-
B8–restricted epitope, suggesting that some serine proteases
may participate in the degradation of DRiPs of EBNA1
before further processing by proteasomes.
 
Materials and Methods
 
Cell Lines and Antibodies.
 
EBV-transformed LCLs 1, 2, 8, 111,
888, and 1088, melanoma cell lines 102mel, 586mel, and 1359mel,
1359 fibroblasts, and HEK 293 cell lines were maintained in RPMI
1640 (Sigma-Aldrich) supplemented with 10% FCS (Gemini)
growth medium. Antibodies from hybridoma HB55 (anti-DR),
HB 95 (anti–class I), HB 144 (anti-DQ), and HB 145 (anti–class II;
American Type Culture Collection) were purified from culture su-
pernatants of hybridoma. FITC-conjugated anti-CD4 and anti-
CD8 were purchased from BD Biosciences.
 
Chemicals.
 
Proteasome inhibitors Z-Ile-Glu(OtBu)-Ala-Leu-
cinal (ZAL) and lactacystin were purchased from Calbio-
chem.  MHC class II pathway inhibitor chloroquine was pur-
chased from Sigma-Aldrich. Protein synthesis inhibitors emetine,
cycloheximide, and puromycin were purchased from Calbio-
chem. Protease inhibitors, including AEBSF, E-64, EST, leupep-
tin, pepstatin A, TLCK, and TPCK were purchased from Calbi-
ochem. All chemicals were dissolved in solvents recommended
by the manufacturers.
 
HLA Typing of Donor PBMCs.
 
HLA serotypes and DNA ge-
notypes of human PBMCs were determined by the National In-
stitutes of Health HLA Laboratory. The HLA genotype of PB-
MCs from donor M was HLA-A
 
*
 
01, 0201, B
 
*
 
08, DR
 
 
 
1
 
*
 
0301,
0401, DQ
 
 
 
1
 
*
 
0201, 0301, DR
 
 
 
3
 
*
 
0101, DR
 
 
 
4
 
*
 
01. The geno-
type for donor Q was HLA-A
 
*
 
01, 6802, B
 
*
 
15, 53, DR
 
 
 
1
 
*
 
0401,
1302, DQ
 
 
 
1
 
*
 
0301, 0501, DR
 
 
 
3
 
*
 
0301, DR
 
 
 
4
 
*
 
0101. The ge-
notype for donor S was HLA-A
 
*
 
0301, 29, B
 
*
 
44, 4501,
DR
 
 
 
1
 
*
 
0401, 0701, DQ
 
 
 
1
 
*
 
0201, 0301, DR
 
 
 
4
 
*
 
01. The ge-
 
notype for 1359mel was HLA-A
 
*
 
01, B
 
*
 
8, 40, CW
 
*
 
03, 07,
DR
 
 
 
1
 
*
 
0401, 17, DQ
 
 
 
1
 
*
 
02, 03, DR
 
 
 
3
 
*
 
0101, 
 
 
 
4
 
*
 
0101. The ge-
notype for donors 1, 2, and 4 was HLA-B
 
*
 
8 and for donor 3
it was HLA-A
 
*
 
01, 30, B
 
*
 
8, 13, CW
 
*
 
06, 07, DR
 
 
 
1
 
*
 
3, 7,
DQ
 
 
 
1
 
*
 
02, DR
 
 
 
3
 
*
 
01, 
 
 
 
4
 
*
 
01.
 
Synthetic EBNA1-Peptides.
 
10 13–15-mer peptides were
made and purified as previously described (11). The purity and
molecular masses of peptides were determined by HPLC and
mass spectrometry.
 
Generation of Human CD8
 
  
 
T Cell Lines and Clones.
 
Human
PBMCs from three HLA-DR4–expressing donors (M, Q, and S)
were used for peptide stimulation in vitro in lymphocyte culture
medium at 1.5 
 
  
 
10
 
5 
 
cells per well in a flat-bottom 96-well plate
as previously described (11). One T cell line from donor M was
generated that showed specific T cell reactivity against peptide-
pulsed 1359mel cells and was blocked by anti–MHC class I
monoclonal antibody. T cell line M was further cloned using lim-
iting dilution methods as previously described (12).
 
Cytokine Release, Cytotoxicity, and ELISPOT Assays.
 
Human
EBNA1-specific T cell clones were identified on the basis of their
ability to release IFN-
 
 
 
. Cytotoxicity and cold target inhibition
assays were performed as previously described (13). In brief, LCL
111 hot target cells were labeled with 100 
 
 
 
Ci Na
 
2
51 
 
CrO4, ei-
ther alone or in the presence of 1 
 
 
 
M EBNA1-P
 
518–526 
 
peptide
for 8 h at 37
 
 
 
C. Target cells were washed three times with RPMI
1640, counted, and then mixed with CD8
 
  
 
T cells at the indi-
cated effector to target (E/T) ratios. Chromium release was mea-
sured after 16 h of incubation. In cold target inhibition assays,
LCL 111 target cells were pulsed with 1 
 
 
 
M EBNA1-P
 
518–526 
 
or
EBNA1-P
 
572–584 
 
peptides for 90 min, washed three times with
RPMI, counted, and incubated with CD8
 
  
 
T cells for 30 min
before the addition of hot target cells. An E/T ratio of 40:1 and a
cold to hot target ratio of 4:10
 
4 
 
were used in these assays. The
percentage of specific lysis was determined from the equation
[(cpm experimental well-cpm spontaneous release)/(cpm maxi-
mum release-cpm spontaneous release)] 
 
  
 
100%. We used the
ELISPOT assay to detect antigen-specific T cells in fresh PBMCs
as previously described (14).
 
Transfection of EBNA1 Expression Constructs.
 
The EBNA1
full-length, EBNA1–green fluorescent protein (GFP), and
EBNA1-GAr-del-GFP constructs have been described (15). A
retroviral construct encoding EBNA1-GFP was generated and
retroviral supernatants of retrovirus were made as previously de-
scribed (16). Ii-EBNA1 (invariant chain, first 80 amino acids,
fused to EBNA1) was constructed by subcloning full-length
EBNA1 into a pTSX expression vector to express as an Ii fusion
protein (17). HEK293 and 1359mel cells were transfected with
LipofectAMINE reagent (Invitrogen) according to the manufac-
turer’s instructions.
 
Effects of MHC Class I and II Antigen Presentation Inhibitors on
CD8
 
  
 
T Cell Recognition.
 
The effects of various inhibitors, in-
cluding proteasome inhibitors, MHC class II antigen-processing
inhibitor, protein synthesis inhibitors, and protease inhibitors on
CD8
 
  
 
T cell activity were examined in HEK293, 1359mel, and
LCL 111 target cells expressing HLA-B8 plus EBNA1-GFP or
EBNA1 genes. Target cells were incubated in the absence or
presence of various concentrations of inhibitors for different peri-
ods of time depending on the type of inhibitors used. The cells
were then washed and counted and cocultured with T cells over-
night for IFN-
 
  
 
release assays. The solvents used to dissolve the
inhibitors, such as DMSO, methanol, and ethanol were also used
as controls. Melanoma-derived TIL 102 CD4
 
  
 
T cell recognition
of 102mel tumor cells was used to demonstrate the specificity of 
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lactacystin and chloroquine inhibitors of MHC class I and II anti-
gen presentation, respectively.
 
Results
 
Generation of MHC Class I–restricted T Cells Specific for
EBNA1.
 
Recent studies demonstrated that human CD4
 
 
 
T cells consistently and predominantly respond to MHC
class II–restricted peptides derived from EBNA1 (9–11,
18), suggesting that EBNA1 can be processed through the
MHC class II pathway for T cell recognition. During the
course of our work on the identification of MHC class II–
restricted EBNA1 peptides, we generated several T cell
lines that are capable of stimulating T cells after cocultur-
ing with EBNA1-P
 
518–530 
 
(YNLRRGTALAIPQ) peptide-
pulsed 1359mel cells. Representative data from one of
these cell lines, designated M3-W1, is shown in Fig. 1 A.
To determine the restriction element for T cell recogni-
tion, we tested M3-W1 T cell activity in response to the
peptide-pulsed target cells in the presence of anti–MHC
class I (HLA-A, HLA-B, and HLA-C), anti–HLA-DR,
anti–HLA-DP, and anti–HLA-DQ or isotype control anti-
bodies. To our surprise, T cell recognition of the EBNA1-
P
 
518–530 
 
peptide by T cell line M3-W1 was specifically
blocked by an anti–MHC class I monoclonal antibody, but
not by anti–HLA-DP, anti-DQ, anti-DR, or isotype con-
trol antibodies (Fig. 1 B). These results suggest that human
M3-W1 T cells recognize a peptide derived from EBNA1
presented by HLA class I molecules.
 
Characterization of T Cell Clones and Their Antigenic Pep-
tides.
 
To further characterize the T cell line M3-W1, we
generated 18 T cell clones by limiting dilution methods.
Recognition of LCL 111 by different T cell clones is pre-
sented in Fig. 2 A. One of the T cell clones (designated
M3W1-B9) with strong T cell reactivity was chosen for
further study. FACS
 
® 
 
analysis revealed that the M3W1-B9
Figure 1. Generation of EBNA1-specific T cells. (A) T cells were
generated from HLA-B8–expressing PBMCs of donor M after in vitro
stimulation with synthetic peptides from EBNA1. 1.5   105 cells per well
of PBMCs were used to generate EBNA1-P518–530 peptide–specific T
cells. Peptides other than those used for repeated stimulations served as
negative controls. For T cell recognition assays, peptides were pulsed onto
1359mel target cells and cocultured with T cells overnight. Cytokine release
assays were performed as previously described (reference 11). (B) T cell
recognition (T cell line M3-W1 from donor M) of 1359mel cells pulsed
with EBNA1-P518–530  peptide was specifically inhibited by antibody
against MHC class I molecules. T cell recognition assays were performed
at an E/T ratio of 1:1. All results are expressed as IFN-  release in picogram/
milliliter and are the averages of duplicate values. All antibodies were used
at a final concentration of 20  g/ml each.
Figure 2. Characterization of EBNA1-specific T cells. (A) Recognition of
LCL 111 by T cell clones derived from the M3-W1 T cell line. (B) FACS®
analysis of M3-W1-B9 T cells for CD8 expression. T cells were stained
with anti–CD4-PE or anti–CD8-FITC. Positive staining for CD8 T cells
is shown as an open histogram and control antibody staining is repre-
sented as a shaded histogram. (C) Identification of minimal EBNA1 T cell
epitope for MHC class I binding. Four different peptides were made and
pulsed onto 1359mel cells at 10  M concentration. After washing, the
peptide-pulsed cells were cocultured with T cells overnight. IFN-  release
was determined from culture supernatants. (D) EBNA1-P518–526 peptide
titration experiment for M3W1-B9 T cell recognition. EBNA1-P518–526
peptide at various concentrations were pulsed on 1359mel cells and used
as target cells to stimulate T cells. A control peptide EBNA1-P 572–584 was
also used at various concentrations. Experiments were repeated twice
with similar results.CTL Recognition of EBNA1 462
T cells were CD8  (Fig. 2 B). Recognition of the EBNA1-
P518–530  peptide by M3W1-B9 CD8   T cells was also
blocked by antibody against MHC class I, but not by MHC
class II or control antibodies, suggesting that these T cell
clones resemble the bulk CD8  T cell line (not depicted).
Because the optimal peptide lengths for MHC class I
molecules are generally 9–10 amino acids, we made three
additional peptides: one 9-mer EBNA1-P518–526 (YNLR-
RGTAL) containing the HLA-B8 peptide binding motif
and two 10-mer peptides (EBNA1-P518–527 and EBNA1-
P519–528) from the parental EBNA1-P518–530 peptide. These
peptides were tested for their ability to stimulate M3W1-
B9 CD8  T cells. As shown in Fig. 2 C, the EBNA1-
P518–526  peptide was recognized more readily by the
M3W1-B9 CD8  T cells than the parental 13-mer pep-
tide. By contrast, both EBNA1-P518–527 (YNLRRGTALA)
and EBNA1-P519–528 (NLRRGTALAI) peptides exhibited
lower or no activity for T cell recognition. Peptide titra-
tion experiments showed that T cell reactivity of the
9-mer EBNA1-P518–526 peptide could be detected at a
concentration of 63 nM (Fig. 2 D). Thus, the 9-mer
EBNA1-P518–526 peptide is optimal for recognition by the
M3W1-B9 CD8  T cells.
EBNA1 Peptides Are Naturally Processed and Presented to
M3-W1-B9 CD8  T Cells. To determine if the T cell
peptide derived from the EBNA1 antigen can be endoge-
nously processed and presented to CD8  T cells, we trans-
fected plasmid DNAs carrying full-length EBNA1-GFP
or EBNA1-GAr-del-GFP into 1359mel and 1359 fibro-
blast cells as targets for T cell recognition. As shown in
Fig. 3 A, M3W1-B9 CD8  T cells recognized 1359mel/
EBNA1-GFP and 1359mel/EBNA1-GAr-del-GFP tar-
get cells equally well, whereas no T cell reactivity was
detected with 1359mel/GFP cells. The expression of
EBNA1 as a fusion protein with GFP allowed us to mon-
itor gene expression and transfection efficiency through-
out the course of the experiments. CD8  T cells also rec-
ognized 1359 fibroblast cells transfected with full-length
EBNA1-GFP cDNA (Fig. 3 B). The transfection effi-
ciency of 1359mel and fibroblasts is  10–15%. T cell rec-
ognition of 1359mel/EBNA1-GFP was also blocked by
antibody against MHC class I, confirming that the recog-
nition is MHC class I restricted (not depicted). To evalu-
ate endogenous processing of EBNA1 in human PBMCs,
we constructed a retrovirus-encoding EBNA1-GFP for
introducing genes into PBMCs. Although the transduc-
tion efficiency of the retrovirus-encoding EBNA1-GFP
into PBMCs from donor M was  10%, we found that T
cell recognition of PBMCs infected with recombinant
retrovirus increased threefold in terms of IFN-  release
from T cells compared with that of uninfected PBMCs
(Fig. 3 C). These results indicate that the MHC class
I–restricted EBNA1 peptides are endogenously processed
and presented to T cells.
M3W1-B9 CD8  T Cells Recognize EBNA1 Peptides Pre-
sented by HLA-B8 Molecules. To determine the restric-
tion element for M3W1-B9 CD8  T cells, we pulsed the
9-mer EBNA1-P518–526 peptide onto various MHC class I 
melanoma cell lines and tested for T cell recognition. We
found that CD8  T cells recognized 1359mel cells pulsed
with the EBNA1-P518–526  peptide, but not other cells
pulsed with the same peptide (Fig. 4 A), suggesting that
HLA-B8 is a putative restriction element for T cell recog-
nition. To test this possibility, we cloned the HLA-B8
cDNA and transfected it into HEK293 cells along with
EBNA1-GFP or EBNA1-GAr-del-GFP and assessed their
ability to present the antigenic peptide to T cells. Although
EBNA1-GFP, EBNA1-GAr-del-GFP, or HLA-B8 ex-
pressed alone in HEK293 cell did not stimulate T cell re-
sponses, HEK293 cells transfected with EBNA1-GFP plus
HLA-B8 or EBNA1-GAr-del-GFP plus HLA-B8 cDNAs
strongly stimulated IFN-  release from CD8  T cells (Fig.
4 B). Although T cell recognition of HEK293 cells trans-
fected with EBNA1-GAr-del-GFP plus HLA-B8 cDNAs
was slightly higher than that of HEK293 cells transfected
with EBNA1-GFP and HLA-B8 cDNAs, we did not ob-
serve any significant inhibitory effect of the GAr domain
on T cell responses (Fig. 4 B). These studies indicate that
Figure 3. Natural processing and presentation of EBNA1 to M3-W1-
B9 CD8  T cells. (A) Recognition of full-length EBNA1-transfected
1359mel cells by M3-W1-B9 T cells. 1359mel cells were transfected with
200 ng EBNA1-GFP or EBNA1-GAr-del-GFP plasmid DNAs using
LipofectAMINE. IFN-  release was determined as described in Fig. 1.
(B) Recognition of 1359 fibroblasts transfected with EBNA1-GFP by
M3-W1-B9 T cells. 1359 fibroblasts were transfected with EBNA1 plasmid
DNA by electroporation. T cell assays were performed at an E/T ratio of
2:1. (C) T cell recognition of autologous PBMCs infected with retroviral/
EBNA1-GFP.Voo et al. 463
HLA-B8 is an antigen-presenting molecule for M3W1-B9
CD8  T cells.
To exclude the possibility that GFP fusion to EBNA1 al-
ters antigen processing and presentation, we tested whether
HEK293 cells cotransfected with HLA-B8 and the native
form of EBNA1 cDNA can stimulate T cells. As shown in
Fig. 4 C, HEK293 cells transfected with EBNA1 plus
HLA-B8 cDNA strongly stimulated IFN-  release from
CD8  T cells, whereas HEK293 cells transfected with ei-
ther one alone failed to stimulate T cell response. These
studies suggest that the native form of EBNA1 protein, like
the GFP-tagged EBNA1, can be processed and presented
to CD8  T cells by the HLA-B8 molecules.
It is well known that dendritic cells have the capacity to
capture and deliver exogenous antigens into the MHC class
I processing pathway (19, 20). To determine whether the
recognition of EBNA1 by M3W1-B9 CD8  T cells
requires the cross-presentation pathway, we transfected
HEK293 with HLA-B8 cDNA or EBNA1-GFP cDNA
separately, and then mixed them (1:1) together as target
cells in a T cell assay. As shown in Fig. 4 D, M3W1-B9
CD8  T cells did not respond to the mixed cells of trans-
fected HEK293/HLA-B8 and HEK293/EBNA1-GFP, but
they actively recognized HEK293 cells cotransfected with
HLA-B8 and EBNA1-GFP cDNAs. These studies suggest
that the coexpression of HLA-B8 and EBNA1 in the same
HEK293 cells is required for T cell recognition by M3W1-
B9 CD8  T cells and that HEK293 cells are not capable of
cross-presenting EBNA1 antigen to T cells.
Recognition and Lysis of EBV  LCL Cells by M3W1-B9 T
Cells. Although peptide-specific CD8  T cells against pu-
tative tumor antigens or peptides can often be generated
from human PBMCs, they show no reactivity with tumor
cells. Possible explanations include the low affinity of the T
cells for the MHC–peptide complexes or the failure of pre-
sentation of naturally processed peptides on the surface of
tumor cells (21). Indeed, EBNA1 peptide-specific CD8  T
cells generated from human PBMCs after in vitro stimula-
tion failed to recognize autologous EBV  LCLs (5). T cell
reactivity was only found when autologous EBV  LCL
cells were pulsed with exogenous protein or peptides (5).
To test whether the CD8  T cells generated in this study
were capable of recognizing naturally processed peptides
on EBV-infected cells, we used several EBV B cell lines as
target cells. As shown in Fig. 5 A, a cytokine release assay
demonstrated that M3W1-B9 CD8  T cells strongly rec-
ognized HLA-B8  LCL 8, 111, and 1088 cells, but did not
respond to HLA-mismatched LCL 1 and 2 cells. To further
test whether M3W1-B9 CD8  T cells can lyse tumor tar-
get cells, we performed chromium release assays. CD8  T
cells specifically lysed LCL 111 cells but not the HLA-mis-
matched LCL1 cells (Fig. 5 B). Cold target inhibition ex-
periments showed that the specific killing of chromium-
labeled (hot) LCL 111 target cells by the M3W1-B9 CD8 
T cells could be inhibited by the 9-mer EBNA1-P518–526
peptide–pulsed unlabeled (cold) LCL 111 cells, but not by
control peptide–pulsed cold LCL 111 cells (Fig. 5 C).
Taken together, these results indicate that the 9-mer
Figure 4. HLA-B8 molecule functions as a restriction
element for M3-W1-B9 CD8  T cells. (A) T cell recognition
of peptide-pulsed HLA-B8–expressing cell lines. (B) Iden-
tification of HLA-B8 molecule as a restriction element for
T cell recognition. HEK293 cells cotransfected with HLA-B8
plus full-length EBNA1-GFP or EBNA1-GAr-del-GFP
cDNAs (with GAr domain deleted) were tested for recog-
nition by M3-W1-B9 CD8  T cells. Positive and negative
signs indicate cotransfection of target cells in the presence
or absence of HLA-B8 cDNA, respectively. (C) Natural
processing and presentation of the native form of EBNA1
for T cell recognition. HEK293 cells cotransfected with
full-length EBNA1 and HLA-B8 cDNAs were cocultured
with M3-W1-B9 CD8  T cells overnight. IFN-  secretion
from T cells was determined by ELISA. (D) Endogenous
generation of HLA-B8–restricted EBNA1 peptide for T
cell recognition. HEK293 cells transfected with HLA-B8
cDNA were mixed with HEK293 cells transfected with
EBNA1-GFP cDNA at a 1:1 ratio. The mixed cells were
then cocultured with M3-W1-B9 CD8  T cells overnight.
IFN-  release from CD8  T cells was measured from culture
supernatants.CTL Recognition of EBNA1 464
EBNA1-P518–526 peptide can specifically block the recogni-
tion and lysis of EBV  LCL 111 cells by the M3W1-B9
CD8  T cells, implying that a similar or identical EBNA1
peptide is endogenously processed and presented to T cells
by HLA-B8 molecules on the surface of EBV  LCL cells
by a mechanism that overrides the inhibitory effect of the
GAr domain on processing and presentation of EBNA1.
Recognition of EBNA1-P518–530 Peptide by EBNA1-specific
CD4  and CD8  T Cells. Because the HLA-B8–restricted
EBNA1-P518–526  peptide overlaps peptides presented by
both HLA-DR1 and HLA-DP3 molecules (Fig. 6 A), we
sought to determine if the same peptide could be recog-
nized by EBNA1-specific CD4  and CD8  T cell clones.
Fig. 6 B shows that the EBNA1-P518–530 peptide could
be recognized by HLA-DR1– and HLA-DP3–restricted
CD4  as well as M3W1-B9 CD8  T cells when pulsed on
their corresponding HLA-matched target cells. However,
the 9-mer EBNA1-P518–526 peptide was recognized only by
CD8  T cells and not by HLA-DR1– and HLA-DP3–
restricted CD4  T cells, suggesting that the short peptide is
specific for CD8  T cells. These results imply that the 13-
mer EBNA1-P518–530 peptide has a dual function as it can
stimulate both CD4  and CD8  T cell responses.
Determination of EBNA1-specific HLA-B8–restricted CD8 
T Cells in Other Donor PBMCs. Next, we tested whether
EBNA1-specific HLA-B8–restricted CD8   T cells are
present in the PBMCs of other donors expressing HLA-B8.
Five donor PBMCs were obtained for ELISPOT assays us-
ing EBNA1-P518–526 peptide–pulsed target cells. NY-ESO-1
peptide–pulsed target cells served as a specific control.
Three of the five donor PBMCs (donors 1, 2, and 3) ex-
press HLA-B8 molecules and are serum positive for EBV,
whereas donor 4 is positive for HLA-B8 expression but is
serum negative for EBV. A mismatched donor PBMC (do-
Figure 5. Specific lysis of HLA-B8–matched EBV-transformed LCLs
by M3-W1-B9 CD8  T cells. (A) Recognition of HLA-B8–matched
LCLs by M3-W1-B9 CD8  T cells. LCLs were cocultured with M3-W1-B9
CD8  T cells at an E/T ratio of 1:1. Mismatched LCLs were used as negative
controls. (B) Specific lysis of HLA-B8–matched LCL 111 cells by CD8 
T cells at different E/T ratios. LCL 1 was used as a negative control. LCL
cells were labeled with 51chromium. Cytolysis by CD8  T cells was deter-
mined in a 16-h chromium release assay. (C) Cold target inhibition of
recognition of LCL 111 cells by M3-W1-B9 CD8  T cells. Lysis of LCLs
by M3-W1-B9 CD8  T cells was specifically inhibited when EBNA1-
P518–526–pulsed cold LCL 111 targets were used. Lysis was tested with an
effector to hot target ratio of 40:1. Cold LCL 111 target cells were pulsed
with EBNA1-P518–526 or EBNA1-P572–584 peptide at a concentration of 1
 M and were mixed with hot targets at a ratio of 4:1. All experiments
were repeated twice with similar results.
Figure 6. Recognition of the EBNA1-P518–530 peptide by CD4  and
CD8  T cells. (A) Alignment of HLA-DR1–, HLA-DP3–, and HLA-B8–
restricted peptides. (B) Recognition of peptide-pulsed target cells by three
different HLA-B8–, HLA-DR1–, and HLA-DP3–restricted T cell lines/
clones. The HLA-DP3–restricted P3-B7 CD4  T cells are described in a
previous study (reference 11). The HLA-DR1–restricted A4.E116 CD4 
T cells, also previously described (reference 10), recognized an HLA-DR1–
restricted EBNA1 peptide.Voo et al. 465
nor 5) served as a negative control. We found that three of
the four HLA-B8  donor PBMCs specifically responded to
the EBNA1-P518–526 peptide (Fig. 7 A). By contrast, neither
PBMCs from HLA-B8  but seronegative nor HLA-B8 
donors responded to the EBNA1-P518–526 peptide (Fig. 7
A). These results suggest that EBNA1-specific, HLA-B8–
restricted CD8  T cells are commonly present in HLA-
B8  EBV-infected individuals. To further test whether
these EBNA1-specific, HLA-B8–restricted CD8  T cells
are capable of recognizing EBV  LCL cells, we established
T cell clones from the PBMCs of donor 3 by limiting dilu-
tion methods. Recognition of HLA-B8–expressing LCL
1088 by these T cell clones is shown in Fig. 7 B. One T
clone, D1-B11, was selected for further testing of its ability
to recognize HLA-B8  EBV  LCL cells. These T cells ex-
hibited strong T cell reactivity against HLA-B8  LCLs 8
and 1088, but did not respond to HLA-B8  LCL 1 and 2
cells (Fig. 7 C). Taken together, these studies suggest that
the PBMCs of EBV-infected donors expressing HLA-B8
molecules contain EBNA1-specific CD8  T cells that are
capable of recognizing HLA-B8  LCL targets.
Inhibition of T Cell Recognition by Proteasome Inhibitors.
Next, we sought to elucidate the mechanism(s) by which
HLA-B8–restricted peptides are generated. One possibility
is that HLA-B8 peptides are generated through the con-
ventional MHC class I pathway. If so, specific inhibitors of
proteasomes should inhibit the degradation of proteins and
thus the presentation of peptides by MHC class I molecules
for T cell recognition (22). Alternatively, MHC class I mole-
cules bind and present peptides in MHC class II compart-
ments, one of which is transported to the plasma membrane
for T cell recognition (23). Because the EBNA1-P518–526
peptide overlaps with HLA-DR1– and HLA-DP3–restricted
peptides that are shown to be endogenously processed and
presented to CD4  T cells (10, 11), MHC class I molecules
might acquire and present a peptide generated through the
MHC class II pathway. To test this possibility, we trans-
fected HEK293 cells with EBNA1-GFP and HLA-B8
cDNAs, and then treated them with different concentra-
tions of ZAL and lactacystin, specific inhibitors of protea-
somes (22). When antigen-specific CD8  T cells were then
cocultured with target cells to evaluate T cell responses, we
found that T cell reactivity of HEK293 transfected with
HLA-B8 plus EBNA1-GFP cDNAs by the M3W1-B9
CD8  T cells decreased with increasing concentrations of
proteasome inhibitor ZAL, but not in the presence of con-
trol DMSO (Fig. 8 A). Similarly, T cell reactivity against
LCL 111 cells was inhibited with increasing concentration
of ZAL inhibitor. To exclude the potential nonspecific ef-
fect of ZAL on T cell recognition, we tested the effects of
ZAL inhibitor on melanoma-reactive TIL102-CD4   T
cells, which recognize an MHC class II–restricted epitope
on the cell surface of 102mel tumor cells, and of P3-B7
CD4   T cells, which recognize HLA-DP3–expressing
HEK293 cells transfected with Ii-EBNA1 as target cells.
The ZAL inhibitor did not have any inhibitory effect on
recognition of target cells by TIL102 CD4  T cells or
P3-B7 T CD4  cells (Fig. 8 A). We also tested the effects
of lactacystin, another specific proteasome inhibitor, on T
cell recognition. As shown in Fig. 8 B, recognition of
1359mel/EBNA1-GFP cells by M3-W1-B9 CD8  T cell
was decreased with increasing concentrations of lactacystin,
whereas no inhibitory effect was observed with TIL102
CD4  T cell recognition of 102mel target cells. These re-
sults suggest that the inhibitory effect of ZAL and lactacys-
tin is specific for the presentation of HLA-B8–restricted
epitope to CD8  T cells, but not for MHC class II antigen
processing and presentation.
To further exclude the possibility that the EBNA1 pep-
tide recognized by the M3W1-B9 CD8  T cells might be
Figure 7. Generation of EBNA1-P518–526 peptide–specific T cells from
HLA-B8–expressing PBMCs. (A) Detection of EBNA1-P518–526 peptide–
reactive T cells from HLA-B8  donor PBMCs. 105 PBMCs were seeded
per well and experiments were performed in quadruplicate wells. An HLA-
A2–restricted NY-ESO-1 peptide served as a control. HLA-mismatched
donor 5 and an HLA-B8  PMBC donor 4 that is seronegative for EBV
were also included. (B) Recognition of LCL 1088 by CD8  T cell clones
from the PBMCs of donor 3. T cells generated from PBMCs were stimu-
lated with EBNA1-P518–526 peptide as described in Fig. 1. Six CD8  T cell
clones were generated from two T cell lines and were capable of recog-
nizing HLA-B8–expressing LCL 1088 target cells. (C) D1-B11 CD8  T
cell recognition of HLA-B8–matched LCLs. LCLs were cocultured with
T cells at an E/T ratio of 1:1. All experiments were repeated twice with
similar results.CTL Recognition of EBNA1 466
processed through MHC class II pathway and then recy-
cled back to MHC class I pathway to be presented by
HLA-B8 molecules, we tested this possibility in the pres-
ence of chloroquine, a lysosomotropic agent that inhibits
MHC class II antigen processing (24). T cell recognition of
HEK293 cells transfected with HLA-B8 plus EBNA1-GFP
cDNAs or LCL 111 by M3W1-B9 CD8  T cells was not
significantly affected after the target cells were treated with
different concentrations of chloroquine (Fig. 8 C). By con-
trast, T cell activity of TIL102-CD4   T cells against
102mel cells was significantly inhibited by chloroquine,
suggesting that chloroquine can specifically inhibit MHC
class II but not class I pathway for antigen presentation.
Taken together, these results suggest that the processing
and presentation of the HLA-B8–restricted EBNA1 pep-
tides require the participation of proteasomes in the MHC
class I pathway.
HLA-B8–restricted EBNA1 Epitope Is Derived from
DRiPs. The GAr domain has been demonstrated to effi-
ciently block its proteasomal degradation of full-length
EBNA1, thus inhibiting the generation of MHC class
I–restricted peptide for T cell recognition. However, this
inhibition may not be absolute, because some T cell
epitopes are still processed and presented to T cells. Alter-
natively, the HLA-B8–restricted T cell epitope might be
derived through the rapid degradation of DRiPs (25, 26),
which have been estimated to constitute upwards of 30% of
newly synthesized proteins and are considered an important
source of peptide for presentation by MHC class I mole-
cules (25–27). We reasoned that if the HLA-B8–restricted
epitope is generated from proteasomal degradation of full-
length EBNA1, the treatment of target cells with protein
synthesis inhibitors would not affect T cell recognition be-
cause the full-length EBNA1 protein is still present after
treatment. Otherwise, it would suggest that the HLA-B8–
restricted epitope is derived from DRiPs rather than
EBNA1. To test these possibilities, we treated HLA-B8–
expressing HEK293/EBNA1-GFP cells with different con-
centrations of irreversible (emetine) and reversible (puro-
mycin and cycloheximide) protein synthesis inhibitors for
1 h. After washing to remove inhibitors, the treated cells
were cocultured with antigen-specific CD8  T cells. Fig. 9
A shows that recognition of target cells by M3W1-B9
CD8  T cells was significantly (94%) inhibited at a low
concentration (1  M) and completely inhibited at a 5  M
concentration of the irreversible inhibitor emetine. By
contrast, no inhibitory effect was observed when HLA-B8–
expressing 293/EBNA1-GFP cells were treated with re-
versible inhibitors puromycin and cycloheximide, respec-
tively. Because blocking protein synthesis should rapidly
decrease the peptide supply required for the export of
MHC class I molecules from the ER to the cell surface as
well as synthesis of MHC class I molecules (25–27), the
treatment of cells with emetine would decrease the overall
antigen presentation by MHC class I molecules. To ex-
clude the possibility that inhibition of T cell recognition of
the HLA-B8–restricted EBNA1 peptide was due to the ex-
pression and export of MHC class I molecules, we pulsed
HLA-B8  1359mel cells with the EBNA1-P518–526 peptide
after the cells were treated with different concentrations of
emetine and washed. T cell recognition of peptide-pulsed
target cells was slightly inhibited (Fig. 9 A), suggesting that
effect of emetine on MHC class I molecules could not ac-
count for the inhibition of T cell recognition. To further
Figure 8. Specific inhibition of T cell recog-
nition of EBNA1 by proteasomes inhibitors.
(A) Blocking of T cell recognition of EBNA1
by a ZAL proteasome inhibitor. HEK 293 cells
cotransfected with EBNA1-GFP were treated
with various concentrations of ZAL inhibitor
for 10 h. After washing, cells were incubated
with T cells overnight for IFN-  release assays.
Various dilutions of DMSO were used as controls.
T cell activity in the absence of inhibitor was
used at 100% activity. Two CD4  T cells were
used to demonstrate the specificity of ZAL inhibi-
tor.  TIL102 and P3-B7 CD4  T cells able to
recognize 102mel and HEK293/DP3/Ii-EBNA1
target cells, respectively, were not inhibited by
ZAL. (B) Inhibition of M3-W1-B9 CD8  T
cell recognition of 1359mel target cells stably
expressing EBNA1-GFP by lactacystin protea-
some inhibitor. The lactacystin inhibitor did not
affect recognition of 102mel tumor cells by
TIL102 CD4  cells. (C) Blocking of MHC class
II antigen processing by chloroquine. Inhibition
of T cell recognition of 102mel cells by TIL102
CD4  was observed after treatment with chloro-
quine in a dose-dependent fashion. By contrast,
T cell recognition of LCL 111 and HEK293
transfected with HLA-B8 and EBNA1-GFP
cDNAs was not significantly affected after the
treatment of chloroquine.Voo et al. 467
test the sensitivity of antigen processing of other tumor an-
tigens, such as tyrosinase-related protein 2 (TRP2), to pro-
tein synthesis inhibition, we treated 1363mel cells (TRP2 
and HLA-A2 ) with different concentrations of emetine
and then tested for their ability to stimulate TRP2-specific
CD8  T cells. As shown in Fig. 9 B, the inhibition of rec-
ognition of 1363mel target cells by TRP2-specific CD8  T
cells increased with the increasing concentrations of eme-
tine. However, there was only 30% inhibition of T cell rec-
ognition at 1  M emetine treatment compared with  90%
inhibition of EBNA1-specific CD8  T cells at the same
concentration of emetine (Fig. 9 A). As expected, T cell
recognition of the TRP2 peptide–pulsed target cells after
the emetine treatment was slightly inhibited (Fig. 9 B). We
also found that the treatment of target cells with emetine at
a 1  M concentration resulted in 20% inhibition of
EBNA1-specific P3-B7 CD4  T cell recognition (not de-
picted). Taken together, these results indicate that new
protein synthesis is necessary and required for the genera-
tion of the HLA-B8–restricted epitope for T cell recogni-
tion, thus implying that DRiPs are the primary source of
CD8  T cell peptides. On the other hand, the processing
and presentation of the TRP2 and CD4  T cell EBNA1
epitopes are less dependent on the production of short-
lived DRiPs.
Serine Proteases Are Involved in the Generation of T Cell
Epitopes. Next, we sought to determine if other proteases
are involved in the degradation of short-lived DRiPs of
EBNA1 because the GAr domain may need to be removed
before they are further degraded by proteasomes. To iden-
tify individual protease inhibitors that might inhibit the
presentation of the HLA-B8–restricted epitope to T cells,
we selected seven protease inhibitors for further testing.
Fig. 10 A shows that two such protease inhibitors, TPCK
and AEBSF, significantly blocked CD8  T cell recognition
of the HLA-B8–expressing HEK293/EBNA1-GFP target
cells when treated for 2 h at the lowest effective concentra-
tions suggested by the manufacturer. None of the other
protease inhibitors were effective, even after treatment for
2 or 8 h. To test whether TPCK or AEBSF affected T cell
recognition of other antigens, we treated 1359mel with the
same concentrations of TPCK or AEBSF as shown in Fig.
10 A. No inhibition was observed for recognition of
1359mel cells by 1359mel-specific CD8  T cells (Fig. 10
B), suggesting that both inhibitors are specific for process-
ing and presentation of the HLA-B8–restricted EBNA1
epitope. TPCK or AEBSF inhibited T cell recognition of
target cells in a dose-dependent manner (Fig. 10 C),
whereas TLCK produced a partial inhibitory effect when
used at a high concentration. Although TLCK and TPCK
have similar specificities, TLCK is unstable in solution ac-
cording to the manufacturer. AEBSF is an irreversible, spe-
cific inhibitor of serine proteases, whereas TPCK is an irre-
versible inhibitor of chymotrypsin and many other serine
and cysteine proteases. These results suggest that serine
proteases are also required for the processing of the HLA-
B8–restricted T cell epitope.
Discussion
Because of its important role in many EBV-associated
cancers, EBNA1 has been suggested as an important target
for immunotherapy (4, 18). However, efforts by several
groups to identify MHC class I–restricted peptides from
EBNA1 have proved disappointing. CD8  T cells were
generated that could recognize the peptide-pulsed target
cells, but failed to recognize EBNA-1–expressing B cell
lines and tumor cells (5). The results presented here dem-
onstrate that CD8  T cells generated from in vitro peptide
stimulation are capable of recognizing 13 and 9-mer
Figure 9. Inhibition of T cell recognition of EBNA1 by protein synthesis
inhibitors. (A) Specific inhibition of M3-W1-B9 CD8  T cell recognition of
HEK293/B8/EBNA1-GFP target cells by an irreversible protein synthesis
inhibitor emetine. HLA-B8–expressing HEK293/EBNA1-GFP target
cells were treated with an emetine inhibitor at three concentrations for
1 h. After three washes, cells were cocultured with M3-W1-B9 CD8  T
cells overnight for IFN-  release assays. Similar experiments were per-
formed for the treatment of cells with cycloheximide or puromycin. To
determine effect of emetine on recognition of MHC class I/EBNA1 peptide
on the cell surface, we also pulsed HLA-B8  1359 cells with the EBNA1-
P 518–526 peptide after the treatment of 1359mel cells with three different
concentration of emetine. (B) Determination of the sensitivity of recognition
of TRP2-specific CD8  T cells to the treatment with emetine. 1363mel
cells were treated with three different concentrations of emetine. After
three washes, the cells were cocultured with TRP2-specific CD8  T
cells. The treated cells pulsed with a TRP2 peptide were used to examine
the effect of emetine on recognition of MHC class I–TRP2 complexes
on the cell surface.CTL Recognition of EBNA1 468
EBNA1 peptides, and that the 9-mer EBNA1 peptide is
the more effectively recognized of the two (Fig. 2 C).
More importantly, our data showed that EBNA1-specific
CD8  T cells can recognize EBNA1/HLA-B8 expressed
by HEK293, 1359mel, and LCL 111 cells (Figs. 3–5), sug-
gesting that EBNA1 could be endogenously processed and
presented by HLA-B8 molecules for T cell recognition.
Although LCLs or HEK293 cells can take up exogenous
EBNA1 protein from dead cells and then process and
present derivative peptides to T cells through cross-presen-
tation (28), our coculture experiments demonstrated that
mixing HLA-B8–expressing HEK293 cells with HEK293
cells transfected with EBNA1 did not confer T cell recog-
nition (Fig. 4 D). Hence, HLA-B8 and EBNA1 must be
expressed in the same HEK293 cells for EBNA1 to be pro-
cessed and presented by HLA-B8 molecules. Like HEK293
cells, LCLs differ from dendritic cells in having a poor ca-
pacity to cross-present antigen to T cells (18–20).
The discrepancy between previous studies and ours with
regard to the recognition of EBV  LCL cells by CD8  T
cells may have several explanations. First, the avidity of T
cells generated from PBMCs stimulated in vitro is a critical
factor. T cells with a low avidity may recognize only the
peptide-pulsed target cells, whereas T cells with a high
avidity would recognize both the peptide-pulsed target
cells, EBV   LCL, and tumor cells. For example, the
EBNA1-specific CD4  T cells described previously by two
groups recognized HLA-DR1–restricted EBNA1 peptide,
but failed to recognize EBV  tumor cells (9, 29). However,
a recent study showed that CD4  T cells recognizing the
same HLA-DR1–restricted peptide also recognized EBV 
BL tumor cells (10). Second, it has been reported that some
CD8  T cells exhibit poor cytolytic activity, but secrete
high levels of cytokines such as IFN-  (30). In another
study, antiviral CD8  T cells were not cytolytic due to
their low level of perforin (31). Our strategy to generate
EBNA1-specific T cells was based on measurement of
IFN-  release, but not on cytolytic activity. We generated
T cell clones by a limiting dilution method and screened
them for high IFN-  release, showing that our CD8  T
cell clones could recognize peptide-pulsed, EBNA1-trans-
fected target cells as well as EBV  B cells based on IFN- 
release assays. Although our T cells clearly lyse EBV 
LCLs, their cytolytic activity is moderate compared with
cytokine release. These issues warrant further investigation
in the near future.
The identification of the HLA-B8–restricted EBNA1
peptide may provide a new opportunity for the develop-
ment of immunotherapy against BL. However, due to
MHC class I down-regulation in BL (4), the usefulness of
the HLA-B8–restricted epitope requires further investiga-
tion. Our study demonstrates that the EBNA1-P518–526 pep-
tide-specific CD8  T cells are readily detectable in the
HLA-B8–expressing donor PBMCs, suggesting that such
Figure 10. Requirement of serine proteases
for the generation of EBNA1 T cell epitope.
(A) Specific inhibition of M3-W1-B9 CD8  T
cell recognition of HEK293/B8/EBNA1-GFP
target cells by protease inhibitors. Target cells
were incubated with various protease inhibitors
for 2 h, washed, and cocultured with CD8  T
cells overnight for IFN-  release assays. Solvents
used to solubilize inhibitors were also used as
controls. Experiments were performed in tripli-
cate wells. CD8  T cell recognition of target
cells was inhibited by treatment with TPCK and
AEBSF inhibitors. (B) Effect of protease inhibitors
on recognition of 1359mel cells by 1359mel-
specific CD8  T cells. (C) Dose-dependent
inhibition of M3-W1-B9 CD8  T cell recogni-
tion of HEK293/B8/EBNA1-GFP target cells
by protease inhibitors. Target cells were treated
with different concentrations of protease inhibi-
tors. After washes, the treated cells were cocul-
tured with M3-W1-B9 CD8  T cells overnight
for IFN-  release assays.Voo et al. 469
CD8  T cell responses to this peptide are commonplace in
HLA-B8   EBV-infected individuals. HLA-B8–restricted
CD8  T cells established from these HLA-B8  donors re-
sponded functionally to the peptide-pulsed target cells as
well as HLA-B8–matched LCLs (Fig. 7), further suggesting
that the EBNA1 T cell peptides are naturally processed and
presented to CD8  T cells. Interestingly, this EBNA1 pep-
tide overlaps with those presented by both DR1 (P514–
527) and DP3 (P518–530) molecules (10, 11). Because our
CD8  T cells recognized HLA-DR1– and HLA-DP3–
restricted peptides (Fig. 6), immunization with this dual
peptide might stimulate both CD4  and CD8  T cell re-
sponses (32). Thus, the findings presented here could con-
tribute to the development of vaccines for the prevention
and treatment of EBV-associated tumors.
The failure to generate CD8  T cells capable of recog-
nizing naturally processed EBNA1 peptide on EBV  cells
has been attributed to the inhibitory effect of the GAr do-
main within EBNA1 on MHC class I–restricted antigen
processing and presentation (6–8). In this study, we showed
that all forms of EBNA1 (native, EBNA1-GFP, and
EBNA1-GAr-del-GFP) conferred T cell recognition when
cotransfected into HEK293 cells with the HLA-B8 cDNA
(Fig. 4, B and C). Hence, it appears that the GAr domain
does not play a significant role in inhibiting the processing
and presentation of the HLA-B8–restricted EBNA1 pep-
tide through the MHC class I pathway. This notion is fur-
ther supported by our data showing that proteasome in-
hibitors can block the processing and presentation of
HLA-B8–restricted EBNA1 peptide for T cell recognition
through the MHC class I pathway (Fig. 8). The failure of
chloroquine, an MHC class II pathway inhibitor, to inhibit
T cell recognition of EBNA1 and HLA-B8–expressing
HEK293 cells and LCL 111 cells further suggests that the
MHC class II pathway does not play an important role in
generating HLA-B8–restricted EBNA1 peptide (Fig. 8).
Our data further indicate that newly synthesized DRiPs,
rather than the full-length EBNA1 antigen, are the major
source of the HLA-B8–restricted epitope (Fig. 9). These
results are consistent with a recent study showing that inhi-
bition of proteasomal degradation by the GAr domain is
not sufficient to prevent presentation of epitopes from the
GAr-containing proteins to the MHC class I pathway (33).
Importantly, the increase in antigenic peptide production
from the GAr-containing proteins correlates with the rate
of protein synthesis (33). Taken together, these data sup-
port a mechanism by which the MHC class I peptides are
derived through the degradation of short-lived DRiPs. The
molecular basis for this mechanism was investigated by
treating target cells with AEBSF and TPCK at a low effec-
tive concentration that resulted in significant inhibition of
T cell recognition. Other protease inhibitors failed to in-
hibit the presentation of the HLA-B8–restricted T cell
epitope to T cells (Fig. 10). Because both AEBSF and
TPCK inhibit serine proteases, we suggest that at least one
or more serine proteases are required for the initial cleavage
of the GAr domain from the DRiPs of EBNA1 before fur-
ther digestion by proteasomes. Thus, our results demon-
strate for the first time that the short-lived DRiPs of
EBNA1 may serve as the primary source of the HLA-B8–
restricted epitope and that their degradation requires partic-
ipation of both serine proteases and proteasomes.
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